Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
BMN 673 (BioMarin)
- Breast cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 4 prior regimens for metastatic disease.
Type of study:
- Patients receive BMN 673 orally once daily.
TGen Clinical Research Services
Scottsdale, Arizona, 95258
Contact: Joyce Schaffer, MSN RN OCN 480-323-1339 firstname.lastname@example.org
Principal Investigator: Ramesh Ramanathan, MD
University of California Los Angeles (UCLA)
Santa Monica, California, United States, 90404
Contact: Lisa M Yonemoto 310-582-4069 email@example.com
Principal Investigator: Zev Wainberg, MD
Indiana University Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Kisha Horan 317-274-4262 firstname.lastname@example.org
Principal Investigator: Lida Mina, MD
University of Michigan Health System Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Nabeela Iqbal 734-232-0759 email@example.com
Principal Investigator: Rashmi Chugh, MD
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Anne Meschwitz 713-745-6773 firstname.lastname@example.org
Principal Investigator: Lauren A Byers, MD
Royal Marsden Hospital
Sutton, United Kingdom, SM2 5PT
Contact: Sonia Serrano +44 (0) 20 8722 4087 Sonia.Serrano@icr.ac.uk
Principal Investigator: Johann de Bono, MD
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.